WO2002019935A1 - Method and system for anticoagulant dose revision - Google Patents
Method and system for anticoagulant dose revision Download PDFInfo
- Publication number
- WO2002019935A1 WO2002019935A1 PCT/US2001/025362 US0125362W WO0219935A1 WO 2002019935 A1 WO2002019935 A1 WO 2002019935A1 US 0125362 W US0125362 W US 0125362W WO 0219935 A1 WO0219935 A1 WO 0219935A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dose
- patient
- warfarin
- response
- current
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention relates generally to a method and system for use in treating a patient with an anticoagulant to optimize drug therapy and to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin.
- the present invention can utilize either drug levels or other surrogate markers to determine the effectiveness of the dosing regimen and, if necessary, to suggest a new more optimal drug dose.
- anticoagulant includes, but is not limited to, warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®, anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifi
- anticoagulant is also intended to mean species which employ any or more of the individual anticoagulants as defined and/or alluded to hereinabove.
- BACKGROUND OF THE INVENTION When a patient begins taking an anticoagulant or any medication for a length of time, a titration of the amount of drug taken by the patient is necessary in order to achieve the optimal benefit of the drug, and at the same time to prevent any undesirable side effects that taking too much of the drug could produce. Thus, there is a continuous balance between taking enough drug in order to gain the benefits from that drug and at the same time not taking so much drug as to illicit a toxic event.
- Bayesian analysis is another method used to relate drug dose to efficacy. This method employs large-scale population parameters to stratify a population in order to better characterize the individuals. This method does not take into account the changes that can occur within a person over time, and as a result cannot reliably estimate dosages.
- Pharmacokinetic compartment modeling has had success with some drugs, but because the models are static and cannot adapt themselves to changes within a population or a patient, they are once again undesirable for dynamically determining drug dosages.
- patient dosing occurs through a cyclic series of events, depicted in flow chart form in Figure 1.
- a drug such as an anticoagulant
- the initial dose is based on the FDA recommended dosage found on the drug label.
- the anticoagulant dose is further refined upon repeated dosing by the physician based on the patient's response to the anticoagulant. Too much anticoagulant could cause the patient to experience toxic anticoagulant effects, and the anticoagulant dose would need to be reduced. Too little anticoagulant could cause the patient not to receive the benefit the anticoagulant therapy could offer, and the dosage would need to be increased.
- the preferred embodiment of the invention requires that a physician determine the percentage of response by the patient to the anticoagulant based on the surrogate markers for that anticoagulant. A relationship is then employed which uses the input parameters described above to determine the next dose for the patient.
- the invention also includes embodiments focused on specific anticoagulants, such as, for example only, Coumadin®, warfarin, substances containing warfarin, etc.
- the invention includes a method for calculating a revised dose of Coumadin® for a patient using Coumadin®, comprising the steps of: accepting as a first input the patient's current Coumadin® dose; accepting as a second input a maximum dose of Coumadin®; accepting as a third input a percent response of the patient based on one or more surrogate markers for said patient; and determining a revised dose, wherein said revised dose is a function of said current dose minus a ratio of the percent response of the patient and a ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
- Another example is a method for determining a dose of warfarin or a substance containing warfarin for a patient, comprising the steps of: administering an initial dose of Warfarin or said substance containing warfarin to the patient; examining the patient to monitor and characterize one or more numerical surrogate markers; determining if a dose change is necessary; and calculating a revised dose as a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
- Each specie of the invention has two preferred embodiments; one which uses actual numerical surrogate markers to calculate a dose, and another embodiment that uses percentages as the numerical input for the surrogate markers.
- Figure 1 shows a flow chart of the process by which revised doses of an anticoagulant are determined, according to the method of the invention described herein.
- Figure 2 shows an apparatus for use in calculating revised doses of an anticoagulant according to the present invention.
- the present invention provides a method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and to prevent an adverse drug response.
- This system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Because the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.
- FIG. 1 shows a flow chart of the overall process of treating a patient using this expert system.
- the actual expert system performs only the steps shown in blocks 10 and 12 of the flow chart.
- This expert system includes a general purpose computer, shown in Figure 2, comprising an input means, preferably a keyboard 20 and/or a mouse 22, an output means 30, preferably a video display screen, a data storage means 50, preferably a hard disk drive, and a processor.
- the expert computer program receives input data from a physician regarding the patient's current anticoagulant dose, the maximal dose range for the anticoagulant, and the percent response of the patient based on the surrogate markers used to monitor the anticoagulant. Also characterized is the patient's response to the last dosing cycle as well as a dose response constant. This allows the expert system to individualize the patient dosing based on the patient's individual response to the anticoagulant.
- the system calculates a revised dosage based on the data input by the physician.
- the software portion of the invention includes a user interface portion 100 to receive the input data and to output the revised dosage information, and a data analysis portion 110, which calculates the new dosage information based on the input data.
- a physician prescribes an anticoagulant for a patient based on the FDA recommended dose on the label of the anticoagulant.
- the physician then re- evaluates the patient, usually daily, either in person or remotely depending on the agent being prescribed.
- the surrogate markers are monitored and sequentially compared to determine if there are any toxicities associated with the anticoagulant.
- the numerical markers will evaluated to see if the desired effect of the anticoagulant is being achieved. Based on this evaluation by the physician, the current anticoagulant dose, the current anticoagulant numerical marker, the desired anticoagulant numerical marker, and the previous anticoagulant numerical marker are then input into the embodiment and the new anticoagulant dose is calculated based on the equation:
- NAD CAD - ⁇ [ ⁇ (CANM - DANM)/CANM)/(1+ (CAD/HIGH))] x CAD ⁇ + LV
- LV ⁇ (RESP x CAD) x [(1+D) - (1+E)]/ abs (1+D) ⁇ / [1.3 ⁇ (CAD/HIGH)]
- CANM Current Anticoagulant Numerical Marker
- DANM Desired Anticoagulant Numerical Marker
- PANM Previous Anticoagulant Numerical Marker
- a physician prescribes an anticoagulant for a patient based on the FDA recommended dose on the label of the anticoagulant.
- the physician then re-evaluates the patient, usually daily, either in person or remotely depending on the agent being prescribed.
- the surrogate markers are monitored and sequentially compared to determine if there are any toxicities associated with the anticoagulant. Also the surrogate markers are evaluated to see if the desired effect of the anticoagulant is being achieved.
- NAD CAD - ⁇ [((PAR - 100)/PAR)/(1+ (CAD/HIGH))] x CAD ⁇ + LV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and prevent an adverse drug response. The system performs the steps shown in blocks (10, 12) of the flow chart. The system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Because the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.
Description
METHOD AND APPARATUS FOR ANTICOAGULANT DOSE REVISION
This document may contain material which is the subject of copyright protection. All rights in such copyrightable material are hereby reserved. RELATED APPLICATION
The present patent application is a continuation-in-part of United States Patent Application Serial Number 09/348,592 filed on July 6, 1999, the entire contents of which are incorporated herein by reference thereto. FIELD OF THE INVENTION
The present invention relates generally to a method and system for use in treating a patient with an anticoagulant to optimize drug therapy and to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. The present invention can utilize either drug levels or other surrogate markers to determine the effectiveness of the dosing regimen and, if necessary, to suggest a new more optimal drug dose.
The term "anticoagulant" as used herein includes, but is not limited to, warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®,
anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifibatide, Integrilin®, lepirudin, Refludan®, nadroparin, Fraxiparine®, oprelvekin, Neumega®, pentosan polysulfate sodium, Elmiron®, reteplase, Retavase®, reviparin, Clivarine®, saruplase, streptokinase, Kabikinase®, Streptase®, tinzaparin, Innohep®, tirofiban, Aggrastat®, unfractionated heparin, low molecular weight heparin, all antithrombotic agents, all vitamin K antagonists, and all substances derived from and/or related to the foregoing substances.
Furthermore, wherever the generic term "anticoagulant" is used herein it is also intended to mean species which employ any or more of the individual anticoagulants as defined and/or alluded to hereinabove. BACKGROUND OF THE INVENTION When a patient begins taking an anticoagulant or any medication for a length of time, a titration of the amount of drug taken by the patient is necessary in order to achieve the optimal benefit of the drug, and at the same time to prevent any undesirable side effects that taking too much of the drug could produce. Thus, there is a continuous balance between taking enough drug in order to gain the benefits from that drug and at the same time not taking so much drug as to illicit a toxic event.
There is large inter-individual variability in the patient pharmocodynamic and pharmacokinetic interactions of drugs. What may be an appropriate drug dose for one individual, may be too much or too little for another. Prior to this invention a
physician was required to estimate the correct drug dosage for a patient and then to experiment with that dosage, usually by trial and error, until the correct dosage was achieved. Likewise, the FDA labeling of a drug suggests dosages based on epidemiological studies and again does not account for inter-individual variability. Non-linear least squares modeling methods involve the use of large amounts of data relating to a general population in order to calculate a best fit. Much like linear regression models, this method cannot take into account the variability between people with the same population characteristics.
Bayesian analysis is another method used to relate drug dose to efficacy. This method employs large-scale population parameters to stratify a population in order to better characterize the individuals. This method does not take into account the changes that can occur within a person over time, and as a result cannot reliably estimate dosages.
Pharmacokinetic compartment modeling has had success with some drugs, but because the models are static and cannot adapt themselves to changes within a population or a patient, they are once again undesirable for dynamically determining drug dosages.
Expert systems have been developed using similar technology to predict drug dosages for immunosuppressant drugs (see, e.g., U.S. Patent Nos. 5,365,948, 5,542,436 and 5,694,950). These algorithms, however, are not generic and only use immunosuppressant blood levels. Each algorithm is specific to an individual immunosuppressant drug. As it stands, these inventions cannot be applied to other drugs and do not have a non-linear feedback loop mechanism.
SUMMARY OF THE INVENTION
According to the present invention, patient dosing occurs through a cyclic series of events, depicted in flow chart form in Figure 1. After an initial examination, an initial dose of a drug, such as an anticoagulant, is prescribed and administered by a physician for a patient. The initial dose is based on the FDA recommended dosage found on the drug label. The anticoagulant dose is further refined upon repeated dosing by the physician based on the patient's response to the anticoagulant. Too much anticoagulant could cause the patient to experience toxic anticoagulant effects, and the anticoagulant dose would need to be reduced. Too little anticoagulant could cause the patient not to receive the benefit the anticoagulant therapy could offer, and the dosage would need to be increased.
The preferred embodiment of the invention requires that a physician determine the percentage of response by the patient to the anticoagulant based on the surrogate markers for that anticoagulant. A relationship is then employed which uses the input parameters described above to determine the next dose for the patient.
The invention also includes embodiments focused on specific anticoagulants, such as, for example only, Coumadin®, warfarin, substances containing warfarin, etc. For example, the invention includes a method for calculating a revised dose of Coumadin® for a patient using Coumadin®, comprising the steps of: accepting as a first input the patient's current Coumadin® dose; accepting as a second input a maximum dose of Coumadin®; accepting as a third input a percent response of the patient based on one or more surrogate markers for said patient; and determining a revised dose, wherein said revised
dose is a function of said current dose minus a ratio of the percent response of the patient and a ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
Another example is a method for determining a dose of warfarin or a substance containing warfarin for a patient, comprising the steps of: administering an initial dose of Warfarin or said substance containing warfarin to the patient; examining the patient to monitor and characterize one or more numerical surrogate markers; determining if a dose change is necessary; and calculating a revised dose as a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
Each specie of the invention has two preferred embodiments; one which uses actual numerical surrogate markers to calculate a dose, and another embodiment that uses percentages as the numerical input for the surrogate markers.
DESCRIPTION OF THE DRAWINGS
Figure 1 shows a flow chart of the process by which revised doses of an anticoagulant are determined, according to the method of the invention described herein. Figure 2 shows an apparatus for use in calculating revised doses of an anticoagulant according to the present invention. DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize
therapy and to prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Because the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers. A method of this invention for use in treating a patient receiving an anticoagulant to optimize therapy and to prevent an adverse anticoagulant response can be implemented in two different embodiments, two of which will each be described separately. Figure 1 shows a flow chart of the overall process of treating a patient using this expert system. The actual expert system, however, performs only the steps shown in blocks 10 and 12 of the flow chart.
This expert system includes a general purpose computer, shown in Figure 2, comprising an input means, preferably a keyboard 20 and/or a mouse 22, an output means 30, preferably a video display screen, a data storage means 50, preferably a hard disk drive, and a processor. The expert computer program receives input data from a physician regarding the patient's current anticoagulant dose, the maximal dose range for the anticoagulant, and the percent response of the patient based on the surrogate markers used to monitor the anticoagulant. Also characterized is the patient's response to the last dosing cycle as well as a dose response constant. This allows the expert system to individualize the patient
dosing based on the patient's individual response to the anticoagulant. The system calculates a revised dosage based on the data input by the physician. The software portion of the invention includes a user interface portion 100 to receive the input data and to output the revised dosage information, and a data analysis portion 110, which calculates the new dosage information based on the input data.
Numerical Surrogate Markers Embodiment
A physician prescribes an anticoagulant for a patient based on the FDA recommended dose on the label of the anticoagulant. The physician then re- evaluates the patient, usually daily, either in person or remotely depending on the agent being prescribed. During the subsequent evaluations by the physician, the surrogate markers are monitored and sequentially compared to determine if there are any toxicities associated with the anticoagulant. Also the numerical markers will evaluated to see if the desired effect of the anticoagulant is being achieved. Based on this evaluation by the physician, the current anticoagulant dose, the current anticoagulant numerical marker, the desired anticoagulant numerical marker, and the previous anticoagulant numerical marker are then input into the embodiment and the new anticoagulant dose is calculated based on the equation:
NAD = CAD - {[{(CANM - DANM)/CANM)/(1+ (CAD/HIGH))] x CAD} + LV where: LV = {(RESP x CAD) x [(1+D) - (1+E)]/ abs (1+D)} / [1.3Λ(CAD/HIGH)]
E = CANM - PANM D = (DANM - PANM) RESP = RESPONSE / 100
and wherein:
NAD = New Anticoagulant Dose
CAD = Current Anticoagulant Dose
CANM = Current Anticoagulant Numerical Marker DANM = Desired Anticoagulant Numerical Marker
PANM = Previous Anticoagulant Numerical Marker
HIGH = The input parameter that is the high dose range for said anticoagulant
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power. Percentage Surrogate Markers Embodiment
In this preferred embodiment, a physician prescribes an anticoagulant for a patient based on the FDA recommended dose on the label of the anticoagulant. The physician then re-evaluates the patient, usually daily, either in person or remotely depending on the agent being prescribed. During the subsequent evaluations by the physician, the surrogate markers are monitored and sequentially compared to determine if there are any toxicities associated with the anticoagulant. Also the surrogate markers are evaluated to see if the desired effect of the anticoagulant is being achieved. Based on this evaluation by the physician, the current anticoagulant dose, and the percent response of the patient to the last dosing based on a surrogate marker are then input into the system and the new anticoagulant dose is calculated based on the equation:
NAD = CAD - {[((PAR - 100)/PAR)/(1+ (CAD/HIGH))] x CAD} + LV where:
LV = {(RESP x CAD) x [(100 - RES) x 0.01]} / [1.3Λ(CAD/HIGH)] RESP = RESPONSE / 100 and wherein:
NAD = New Anticoagulant Dose CAD = Current Anticoagulant Dose PAR = Percent response of patient to surrogate marker RES = Percent response of patient to last dosing based on surrogate marker
HIGH = The input parameter that is the high dose range for said anticoagulant
RESPONSE = Total dose available for individualizing patient dose Λ = Raised to the nth power. This cycle of repeated re-evaluation of the numerical surrogate markers is continued as long as the patient is required to take the anticoagulant.
Two embodiments of the invention have been described, one using numerical markers and one using a percentage surrogate marker.
Although the invention has been described in detail in the foregoing for the purpose of illustration, it is to be understood that such detail is solely for that purpose and that variations can be made therein by those of ordinary skill in the art without departing from the spirit and scope of the invention as defined by the following claims, including all equivalents thereof.
Claims
1. A method for calculating a revised dose of an anticoagulant for a patient using said anticoagulant, comprising the steps of: accepting as a first input the patient's current anticoagulant dose; accepting as a second input a maximum dose of the anticoagulant; accepting as a third input a percent response of the patient based on one or more surrogate markers for said patient; and determining a revised dose, wherein said revised dose is a function of said current dose minus a ratio of the percent response of the patient and a ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
2. The method of claim 1 , wherein: said determining step includes determining said revised dose based on the equation
RAD = CAD - {[((PAR - 100)/PAR)/(1+ (CAD/HIGH))] x CAD} + LV where:
LV = {(RESP x CAD) x [(100 - RES) x 0.01]} / [1.3Λ(CAD/HIGH)]
RESP = RESPONSE / 100 and wherein:
RAD = Revised Anticoagulant Dose
CAD = Current Anticoagulant Dose
PAR = Percent response of patient to surrogate marker
RES = Percent response of patient to last dosing based on surrogate marker
HIGH = The input parameter that is the high dose range for said anticoagulant
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the n h power.
3. The method of claim 1 , wherein: said anticoagulant is selected from a group comprising warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®, anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifibatide, Integrilin®, lepirudin, Refludan®, nadroparin, Fraxiparine®, oprelvekin, Neumega®, pentosan polysulfate sodium, Elmiron®, reteplase, Retavase®, reviparin, Clivarine®, saruplase, streptokinase, Kabikinase®, Streptase®, tinzaparin, Innohep®, tirofiban, Aggrastat®, unfractionated heparin, low molecular weight heparin, all antithrombotic agents, all vitamin K antagonists, and all substances derived from and/or related to the foregoing substances.
4. A method for calculating a revised dose of a anticoagulant for a patient using said anticoagulant comprising the steps of: accepting as a first input the patient's current anticoagulant dose; accepting as a second input the maximum dose of the anticoagulant; accepting as a third input one or more numerical markers indicating a response of the patient; and calculating said revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
5. The method of claim 4, wherein: said calculating step includes calculating said revised dose based on the equation
RAD = CAD - {[((CANM - DANM)/CANM>/<1+ (CAD/HIGH))] x CAD} + LV where:
LV = {(RESP x CAD) x [(1 +D) - (1 +E)]/ abs (1 +D)} / [1.3Λ(CAD/HIGH)]
E = CANM - PANM
D = DDNM - PDNM
RESP = RESPONSE / 100 and wherein:
RAD = Revised Anticoagulant Dose
CAD = Current Anticoagulant Dose CANM = Current Anticoagulant Numerical Marker DANM = Desired Anticoagulant Numerical Marker PANM = Previous Anticoagulant Numerical Marker HIGH = The input parameter that is the high dose range for said anticoagulant
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of Λ = Raised to the nth power.
6. The method of claim 4, wherein: said anticoagulant is selected from a group comprising warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®, anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifibatide, Integrilin®, lepirudin, Refludan®, nadroparin, Fraxiparine®, oprelvekin, Neumega®, pentosan polysulfate sodium, Elmiron®, reteplase, Retavase®, reviparin, Clivarine®, saruplase, streptokinase, Kabikinase®, Streptase®, tinzaparin, Innohep®, tirofiban, Aggrastat®, unfractionated heparin, low molecular weight heparin, all antithrombotic agents, all vitamin K antagonists, and all substances derived from and/or related to the foregoing substances.
7. A method for determining a dose of a anticoagulant for a patient, comprising the steps of: administering an initial dose of said anticoagulant to the patient; evaluating the patient to monitor and characterize one or more numerical surrogate markers; determining, based on said numerical surrogate markers, if a dose change for said anticoagulant is necessary; and calculating a revised dose as a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
8. The method of claim 7, wherein: said anticoagulant is selected from a group comprising warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®, anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifibatide, Integrilin®, lepirudin, Refludan®, nadroparin, Fraxiparine®, oprelvekin, Neumega®, pentosan polysulfate sodium, Elmiron®, reteplase, Retavase®, reviparin, Clivarine®, saruplase, streptokinase, Kabikinase®, Streptase®, tinzaparin, Innohep®, tirofiban, Aggrastat®, unfractionated heparin, low molecular weight heparin, all antithrombotic agents, all vitamin K antagonists, and all substances derived from and/or related to the foregoing substances.
9. A method for determining a dose of an anticoagulant for a patient, comprising the steps of : administering an initial dose of said anticoagulant to the patient; examining the patient to monitor and characterize one or more numerical surrogate markers; determining if a dose change is necessary; and calculating a revised dose as a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
10. A method for calculating a revised dose of an anticoagulant for a patient, comprising the steps of: accepting as input the patient's current anticoagulant dose; accepting as input the maximum dose of the anticoagulant; accepting as input the percent response of the patient based on surrogate markers; and calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said percent response of the patient based on said surrogate markers.
11. A method for calculating a revised dose of an anticoagulant for a patient, comprising the steps of: accepting as input a patient's current anticoagulant dose; accepting as input a maximum dose of the anticoagulant; accepting as input the previous, current and desired values of one or more numerical markers indicating the response of the patient; and calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said previous, current and desired values of said numerical markers.
12. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a method comprising the steps of: accepting as input a patient's current anticoagulant dose; accepting as input a maximum dose of the anticoagulant; accepting as input a percent response of a patient based on surrogate markers; and calculating a revised dose, wherein said revised dose is a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
13. The storage device of claim 12, wherein: said anticoagulant is selected from a group comprising warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®, anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifibatide, Integrilin®, lepirudin, Refludan®, nadroparin, Fraxiparine®, oprelvekin, Neumega®, pentosan polysulfate sodium, Elmiron®, reteplase, Retavase®, reviparin, Clivarine®, saruplase, streptokinase, Kabikinase®, Streptase®, tinzaparin, Innohep®, tirofiban, Aggrastat®, unfractionated heparin, low molecular weight heparin, all antithrombotic agents, all vitamin K antagonists, and all substances derived from and/or related to the foregoing substances.
14. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a method comprising the steps of: accepting as input the patient's current anticoagulant dose; accepting as input the maximum dose of the anticoagulant; accepting as input one or more numerical markers indicating the response of the patient; and calculating a revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
15. An apparatus for calculating a revised dose of an anticoagulant for a patient comprising: means for accepting as input one or more markers which indicate a patient's response to a dose of said anticoagulant; means for accepting as input the patient's current anticoagulant dose; means for accepting as input the maximum dose of the anticoagulant; and means for calculating a revised dose of the anticoagulant as a function of said markers, said current anticoagulant dose, and said maximum anticoagulant dose.
16. The apparatus of claim 15, wherein: said markers are actual numerical markers
17. The apparatus of claim 15, wherein: said markers are surrogate markers representing a percent response of the patient to the anticoagulant.
18. The apparatus of claim 15, wherein: said revised dose is calculated by the following equation: RAD = CAD - {[((CANM - DANM)/CANM>/<1+ (CAD/HIGH))] x CAD} + LV where:
LV = {(RESP x CAD) x [(1 +D) - (1 +E)]/ abs (1 +D)} / [1.3Λ(CAD/HIGH)] E = CANM - PANM D = DDNM - PDNM RESP = RESPONSE / 00, and wherein:
RAD = Revised Anticoagulant Dose
CAD = Current Anticoagulant Dose
CANM = Current Anticoagulant Numerical Marker
DANM = Desired Anticoagulant Numerical Marker
PANM = Previous Anticoagulant Numerical Marker
HIGH = The input parameter that is the high dose range for said anticoagulant
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power.
19. The apparatus of claim 15, wherein: said revised dose is calculated by the equation:
RAD = CAD - {[((PAR - 100)/PAR>/{1+ (CAD/HIGH))] x CAD} + LV where:
LV = {(RESP x CAD) x [(100 - RES) x 0.01]} / [1.3Λ(CAD/HIGH)]
RESP = RESPONSE / 100 and wherein:
RAD = Revised Anticoagulant Dose
CAD = Current Anticoagulant Dose
PAR = Percent response of patient to surrogate marker
RES = Percent response of patient to last dosing based on surrogate marker
HIGH = The input parameter that is the high dose range for said anticoagulant RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of Λ = Raised to the nth power.
20. The apparatus of claim 15, wherein: said anticoagulant is selected from a group comprising warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®, anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifibatide, Integrilin®, lepirudin, Refludan®, nadroparin, Fraxiparine®, oprelvekin, Neumega®, pentosan polysulfate sodium, Elmiron®, reteplase, Retavase®, reviparin, Clivarine®, saruplase, streptokinase, Kabikinase®, Streptase®, tinzaparin, Innohep®, tirofiban, Aggrastat®, unfractionated heparin, low molecular weight heparin, all antithrombotic agents, all vitamin K antagonists, and all substances derived from and/or related to the foregoing substances.
21. A method for calculating a revised dose of Coumadin® for a patient using Coumadin®, comprising the steps of: accepting as a first input the patient's current Coumadin® dose; accepting as a second input a maximum dose of Coumadin®; accepting as a third input a percent response of the patient based on one or more surrogate markers for said patient; and determining a revised dose, wherein said revised dose is a function of said current dose minus a ratio of the percent response of the patient and a ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
22. The method of claim 21 , wherein: said determining step includes determining said revised dose based on the equation
RCD = CCD - {[((PCR - 100)/PCR)/<1+ (CCD/HIGH))] x CCD} + LV where:
LV = {(RESP x CCD) x [(100 - RES) x 0.01]} / [1.3Λ(CCD/HIGH)] RESP = RESPONSE / 100 and wherein:
RCD = Revised Coumadin® Dose CCD = Current Coumadin® Dose PCR = Percent response of patient to surrogate marker RES = Percent response of patient to last dosing based on surrogate marker
HIGH = The input parameter that is the high dose range for Coumadin® RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of Λ = Raised to the nth power.
23. A method for calculating a revised dose of Coumadin® for a patient using Coumadin®, comprising the steps of: accepting as a first input the patient's current Coumadin® dose; accepting as a second input the maximum dose of Coumadin®; accepting as a third input one or more numerical markers indicating a response of the patient; and calculating said revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
24. The method of claim 23, wherein: said calculating step includes calculating said revised dose based on the equation
RCD = CCD - {[((CCNM - DCNM)/CCNM)/<1+ (CCD/HIGH))] x CCD} + LV where:
LV = {(RESP x CCD) x [(1 +D) - (1 +E)]/ abs (1+D)} / [1.3Λ(CCD/HIGH)]
E = CCNM - PCNM
D = DCNM - PCNM
RESP = RESPONSE / 100 and wherein:
RCD = Revised Coumadin® Dose
CCD = Current Coumadin® Dose
CCNM = Current Coumadin® Numerical Marker
DCNM = Desired Coumadin® Numerical Marker
PCNM = Previous Coumadin® Numerical Marker
HIGH = The input parameter that is the high dose range for Coumadin®
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power.
25. A method for determining a dose of Coumadin® for a patient, comprising the steps of: administering an initial dose of Coumadin® to the patient; evaluating the patient to monitor and characterize one or more numerical surrogate markers; determining, based on said numerical surrogate markers, if a dose change for Coumadin® is necessary; and calculating a revised dose as a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
26. A method for determining a dose of Coumadin® for a patient, comprising the steps of : administering an initial dose of Coumadin® to the patient; examining the patient to monitor and characterize one or more numerical surrogate markers; determining if a dose change is necessary; and calculating a revised dose as a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
27. A method for calculating a revised dose of Coumadin® for a patient, comprising the steps of: accepting as input the patient's current Coumadin® dose; accepting as input the maximum dose of Coumadin®; accepting as input the percent response of the patient based on surrogate markers; and calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said percent response of the patient based on said surrogate markers.
28. A method for calculating a revised dose of Coumadin® for a patient, comprising the steps of: accepting as input a patient's current Coumadin® dose; accepting as input a maximum dose of Coumadin®; accepting as input the previous, current and desired values of one or more numerical markers indicating the response of the patient; and calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said previous, current and desired values of said numerical markers.
29. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a method comprising the steps of: accepting as input a patient's current Coumadin® dose; accepting as input a maximum dose of Coumadin®; accepting as input a percent response of a patient based on surrogate markers; and calculating a revised dose, wherein said revised dose is a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
30. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a method comprising the steps of: accepting as input the patient's current Coumadin® dose; accepting as input the maximum dose of Coumadin®; accepting as input one or more numerical markers indicating the response of the patient; and calculating a revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
31. An apparatus for calculating a revised dose of Coumadin® for a patient comprising: means for accepting as input one or more markers which indicate a patient's response to a dose of Coumadin®; means for accepting as input the patient's current Coumadin® dose; means for accepting as input the maximum dose of Coumadin®; and means for calculating a revised dose of Coumadin® as a function of said markers, said current Coumadin® dose, and said maximum Coumadin® dose.
32. The apparatus of claim 31 , wherein: said markers are actual numerical markers
33. The apparatus of claim 31 , wherein: said markers are surrogate markers representing a percent response of the patient to Coumadin®.
34. The apparatus of claim 31 , wherein: said revised dose is calculated by the following equation:
RCD = CCD - {[((CCNM - DCNM)/CCNM)/<1+ (CCD/HIGH))] x CCD} + LV where:
LV = {(RESP x CCD) x [(1 +D) - (1 +E)]/ abs (1 +D)} / [1.3Λ(CCD/HIGH)]
E = CCNM - PCNM
D = DCNM - PCNM
RESP = RESPONSE / 100, and wherein:
RCD = Revised Coumadin® Dose
CCD = Current Coumadin® Dose
CCNM = Current Coumadin® Numerical Marker
DCNM = Desired Coumadin® Numerical Marker
PCNM = Previous Coumadin® Numerical Marker
HIGH = The input parameter that is the high dose range for Coumadin®
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power.
35. The apparatus of claim 31 , wherein: said revised dose is calculated by the equation: RCD = CCD - {[((PCR - 100)/PCR}/(1+ (CCD/HIGH))] x CCD} + LV where:
LV = {(RESP x CCD) x [(100 - RES) x 0.01 ]} / [1.3Λ(CCD/HIGH)] RESP = RESPONSE / 100 and wherein:
RCD = Revised Coumadin® Dose CCD = Current Coumadin® Dose PCR = Percent response of patient to surrogate marker RES = Percent response of patient to last dosing based on surrogate marker
HIGH = The input parameter that is the high dose range for Coumadin® RESPONSE = Total dose available for individualizing patient dos Λ = Raised to the nth power.
36. A method for calculating a revised dose of warfarin or a substance containing warfarin for a patient using warfarin or said substance containing warfarin, comprising the steps of: accepting as a first input the patient's current warfarin or said substance containing warfarin dose; accepting as a second input a maximum dose of warfarin or said substance containing warfarin; accepting as a third input a percent response of the patient based on one or more surrogate markers for said patient; and determining a revised dose, wherein said revised dose is a function of said current dose minus a ratio of the percent response of the patient and a ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
37. The method of claim 36, wherein: said determining step includes determining said revised dose based on the equation
RWD = CWD - {[((PWR - 100)/PWR>/(1+ (CWD/HIGH))] x CWD} + LV where:
LV = {(RESP x CWD) x [(100 - RES) x 0.01]} / [1.3Λ(CWD/HIGH)]
RESP = RESPONSE / 100 and wherein:
RWD = Revised Warfarin or said substance containing warfarin Dose
CWD = Current Warfarin or a substance containing warfarin Dose
PWR = Percent response of patient to surrogate marker
RES = Percent response of patient to last dosing based on surrogate marker
HIGH = The input parameter that is the high dose range for warfarin or said substance containing warfarin
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power.
38. A method for calculating a revised dose of warfarin or a substance containing warfarin for a patient using warfarin or said substance containing warfarin comprising the steps of: accepting as a first input the patient's current warfarin or said substance containing warfarin dose; accepting as a second input the maximum dose of warfarin or said substance containing warfarin; accepting as a third input one or more numerical markers indicating a response of the patient; and calculating said revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
39. The method of claim 38, wherein: said calculating step includes calculating said revised dose based on the equation
RWD = CWD - {[((CWNM - DWNM)/CWNM)/<1+ (CWD/HIGH))] x CWD} + LV where:
LV = {(RESP x CWD) x [(1+D) - (1+E)]/ abs (1+D)} / [1.3Λ(CWD/HIGH)]
E = CWNM - PWNM
D = DWNM - PWNM
RESP = RESPONSE / 100 and wherein:
RWD = Revised Warfarin or said substance containing warfarin Dose
CWD = Current Warfarin or said substance containing warfarin Dose
CWNM = Current Warfarin or said substance containing warfarin Numerical Marker
DWNM = Desired Warfarin or said substance containing warfarin Numerical Marker
PWNM = Previous Warfarin or said substance containing warfarin Numerical Marker
HIGH = The input parameter that is the high dose range for warfarin or said substance containing warfarin
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power.
40. A method for determining a dose of warfarin or a substance containing warfarin for a patient, comprising the steps of: administering an initial dose of warfarin or said substance containing warfarin to the patient; evaluating the patient to monitor and characterize one or more numerical surrogate markers; determining, based on said numerical surrogate markers, if a dose change for warfarin or said substance containing warfarin is necessary; and calculating a revised dose as a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
41. A method for determining a dose of warfarin or a substance containing warfarin for a patient, comprising the steps of : administering an initial dose of warfarin or said substance containing warfarin to the patient; examining the patient to monitor and characterize one or more numerical surrogate markers; determining if a dose change is necessary; and calculating a revised dose as a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
42. A method for calculating a revised dose of warfarin or a substance containing warfarin for a patient, comprising the steps of: accepting as input the patient's current warfarin or said substance containing warfarin dose; accepting as input the maximum dose of warfarin or said substance containing warfarin; accepting as input the percent response of the patient based on surrogate markers; and calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said percent response of the patient based on said surrogate markers.
43 . A method for calculating a revised dose of warfarin or a substance containing warfarin for a patient, comprising the steps of: accepting as input a patient's current warfarin or said substance containing warfarin dose; accepting as input a maximum dose of warfarin or said substance containing warfarin; accepting as input the previous, current and desired values of one or more numerical markers indicating the response of the patient; and calculating a revised dose, wherein said revised dose is a function of said current dose, said maximum dose, and said previous, current and desired values of said numerical markers.
44. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a method comprising the steps of: accepting as input a patient's current warfarin or a substance containing warfarin dose; accepting as input a maximum dose of warfarin or said substance containing warfarin; accepting as input a percent response of a patient based on surrogate markers; and calculating a revised dose, wherein said, revised dose is a function of said current dose minus the ratio of a percent response of the patient and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
45. A storage device having stored thereon an ordered set of instructions which, when executed by a computer, performs a method comprising the steps of: accepting as input the patient's current warfarin or a substance containing warfarin dose; accepting as input the maximum dose of warfarin or said substance containing warfarin; accepting as input one or more numerical markers indicating the response of the patient; and calculating a revised dose, wherein said revised dose is a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
46. An apparatus for calculating a revised dose of warfarin or a substance containing warfarin for a patient, comprising: means for accepting as input one or more markers which indicate a patient's response to a dose of warfarin or said substance containing warfarin; means for accepting as input the patient's current warfarin or said substance containing warfarin dose; means for accepting as input the maximum dose of warfarin or said substance containing warfarin; and means for calculating a revised dose of warfarin or said substance containing warfarin as a function of said markers, said current warfarin or said substance containing warfarin dose, and said maximum warfarin or said substance containing warfarin dose.
47. The apparatus of claim 46, wherein: said markers are actual numerical markers
48. The apparatus of claim 46, wherein: said markers are surrogate markers representing a percent response of the patient to warfarin or said substance containing warfarin.
49. The apparatus of claim 46, wherein: said revised dose is calculated by the following equation:
RWD = CWD - {[((CWNM - DWNM)/CWNM)/(1+ (CWD/HIGH))] x CWD} + LV where:
LV = {(RESP x CWD) x [(1+D) - (1+E)]/ abs (1+D)} / [1.3Λ(CWD/HIGH)]
E = CWNM - PWNM
D = DWNM - PWNM
RESP = RESPONSE / 100, and wherein:
RWD = Revised Warfarin or said substance containing warfarin Dose
CWD = Current Warfarin or said substance containing warfarin Dose
CWNM = Current Warfarin or said substance containing warfarin Numerical Marker
DWNM = Desired Warfarin or said substance containing warfarin Numerical Marker
PWNM = Previous Warfarin or said substance containing warfarin Numerical Marker
HIGH = The input parameter that is the high dose range for warfarin or said substance containing warfarin
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power.
50. The apparatus of claim 46, wherein: said revised dose is calculated by the equation:
RWD = CWD - {[((PWR - 100)/PWR)/(1+ (CWD/HIGH))] x CWD} + LV where:
LV = {(RESP x CWD) x [(100 - RES) x 0.01 ]} / [1.3Λ(CWD/HIGH)] RESP = RESPONSE / 100 and wherein:
RWD = Revised Warfarin or said substance containing warfarin Dose
CWD = Current Warfarin or said substance containing warfarin Dose
PWR = Percent response of patient to surrogate marker
RES = Percent response of patient to last dosing based on surrogate marker
HIGH = The input parameter that is the high dose range for warfarin or said substance containing warfarin
RESPONSE = Total dose available for individualizing patient dose abs = The absolute value of
Λ = Raised to the nth power.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2001284868A AU2001284868A1 (en) | 2000-08-24 | 2001-08-13 | Method and system for anticoagulant dose revision |
| CA002419431A CA2419431A1 (en) | 2000-08-24 | 2001-08-13 | Method and system for anticoagulant dose revision |
| EP01963959A EP1311202A4 (en) | 2000-08-24 | 2001-08-13 | Method and system for anticoagulant dose revision |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/644,503 US6942614B1 (en) | 1999-07-06 | 2000-08-24 | Method and system for use in treating a patient with an anticoagulant to optimize therapy and prevent an adverse drug response |
| US09/644,503 | 2000-08-24 | ||
| CA002401913A CA2401913A1 (en) | 1999-07-06 | 2002-09-06 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002019935A1 true WO2002019935A1 (en) | 2002-03-14 |
Family
ID=32928334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/025362 WO2002019935A1 (en) | 2000-08-24 | 2001-08-13 | Method and system for anticoagulant dose revision |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1311202A4 (en) |
| AU (1) | AU2001284868A1 (en) |
| WO (1) | WO2002019935A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058373A2 (en) * | 2003-12-12 | 2005-06-30 | Petra Biotek, Inc. | Methods, program products, and systems for single and multi-agent dosing |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5365948A (en) * | 1992-08-21 | 1994-11-22 | J & W Mcmichael Software Inc. | Method for use in treating a patient with FK 506 to prevent an adverse immune response |
| US5694950A (en) * | 1992-08-21 | 1997-12-09 | J & W Mcmichael Software, Inc. | Method and system for use in treating a patient with immunosuppresants using whole blood level criteria to prevent an adverse immune response |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267116B1 (en) * | 1999-07-06 | 2001-07-31 | The Rxfiles Corporation | Method and system for use in treating a patient with any drug to optimize therapy and prevent an adverse drug |
-
2001
- 2001-08-13 AU AU2001284868A patent/AU2001284868A1/en not_active Abandoned
- 2001-08-13 EP EP01963959A patent/EP1311202A4/en not_active Ceased
- 2001-08-13 WO PCT/US2001/025362 patent/WO2002019935A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5365948A (en) * | 1992-08-21 | 1994-11-22 | J & W Mcmichael Software Inc. | Method for use in treating a patient with FK 506 to prevent an adverse immune response |
| US5542436A (en) * | 1992-08-21 | 1996-08-06 | J & W Mcmichael Software Inc | System for use in treating a patient with FK 506 to prevent an adverse immune response |
| US5694950A (en) * | 1992-08-21 | 1997-12-09 | J & W Mcmichael Software, Inc. | Method and system for use in treating a patient with immunosuppresants using whole blood level criteria to prevent an adverse immune response |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1311202A4 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058373A2 (en) * | 2003-12-12 | 2005-06-30 | Petra Biotek, Inc. | Methods, program products, and systems for single and multi-agent dosing |
| WO2005058373A3 (en) * | 2003-12-12 | 2005-12-29 | Petra Biotek Inc | Methods, program products, and systems for single and multi-agent dosing |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1311202A4 (en) | 2007-04-18 |
| AU2001284868A1 (en) | 2002-03-22 |
| EP1311202A1 (en) | 2003-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6942614B1 (en) | Method and system for use in treating a patient with an anticoagulant to optimize therapy and prevent an adverse drug response | |
| Willmann et al. | Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations | |
| Soares et al. | A mixture model for water uptake, degradation, erosion and drug release from polydisperse polymeric networks | |
| Wallin et al. | Model‐based neutrophil‐guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information | |
| Cella et al. | A model‐based approach to dose selection in early pediatric development | |
| US20160279329A1 (en) | System and method for drug delivery | |
| EP1612708A1 (en) | Clinical trial phase simulation method and clinical trial phase simulator for drug trials | |
| Deal et al. | Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series | |
| Cote et al. | Persistent pulmonary embolism rates following total knee arthroplasty even with prophylactic anticoagulants | |
| US6575169B2 (en) | Method and apparatus for use in treating a patient with any drug to optimize therapy and prevent an adverse drug | |
| Mazzocco et al. | Prediction of response to temozolomide in low‐grade glioma patients based on tumor size dynamics and genetic characteristics | |
| CA3142237A1 (en) | Method for determining an optimal drug dosing regimen | |
| Baron et al. | Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study | |
| Kakara et al. | Population pharmacodynamic analysis of LDL‐cholesterol lowering effects by statins and co‐medications based on electronic medical records | |
| WO2002019935A1 (en) | Method and system for anticoagulant dose revision | |
| WO2008118817A3 (en) | Improved assessment and reporting of the efficacy and safety of drugs and food supplements | |
| CA2419431A1 (en) | Method and system for anticoagulant dose revision | |
| Barras et al. | Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations | |
| Kumar et al. | The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose | |
| Delavenne et al. | Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery | |
| Sahlén et al. | Direct oral anticoagulation versus warfarin in left ventricular thrombus: pooled analysis of randomized controlled trials | |
| Imperiale et al. | Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis | |
| Baker et al. | Inference for meta‐analysis with a suspected temporal trend | |
| Scott et al. | Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients | |
| Nielsen et al. | Population dose‐response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2419431 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001963959 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001963959 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |